In an interview with Pharmacy Times, City of Hope researchers discuss a preclinical platform designed to redirect CAR T cells after infusion and how pharmacists could help bring this adaptable approach into clinical practice.
|Videos|November 10, 2021
Areas of Concern When Combining, Sequencing Liver-directed Therapy With Systemic Therapy for Gastrointestinal NETs
Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, discusses areas of concern when approaching the combination and sequencing of liver-directed therapy with systemic therapy.
Advertisement
Pharmacy Times interviewed Gaby Gabriel, MD, program director, interventional radiology residency and assistant program director, diagnostic radiology residency, University of Kentucky, on his presentation at the 2021 NANETS Multidisciplinary Neuroendocrine Tumors (NETs) Medical Virtual Symposium discussing sequencing and combination of liver-directed therapy (LDT) with systemic therapies.
During the interview, Gabriel discussed areas of concern when approaching the combination and sequencing of LDT with systemic therapy when treating patients with gastrointestinal NETs.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
SubscribeAdvertisement
Related to this article
In an interview with Pharmacy Times, LINKER-SMM1 study investigator Paula Rodríguez-Otero, MD, PhD, a hematologist at Clínica Universidad de Navarra in Pamplona, Spain, explains how researchers selected high-risk patients and how she weighs infections against the potential to prevent progression to active disease.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
Investigational inhaled stem cells for COPD raise questions about lasting clinical benefit and the pharmacy controls needed to deliver a living-cell product through a nebulizer.
A suspected plague death in Russia has renewed attention on the rare infection. Here's how to spot pneumonic plague and which antibiotics the CDC recommends.
In an interview with Pharmacy Times, Abdulkader Rahmo, PhD, discusses investigational inhaled cell therapy for COPD, the evidence needed to establish lasting clinical benefit, and pharmacists’ potential role in its delivery.
The gap is not a paperwork inconvenience—it is a cash flow problem with clinical consequences.
Advertisement
Advertisement